<?xml version="1.0" encoding="utf-8"?>
<html madcap:lastblockdepth="4" madcap:lastheight="878" madcap:lastwidth="701" xmlns:madcap="http://www.madcapsoftware.com/Schemas/MadCap.xsd">
 <head>
 </head>
 <body>
  <h1>
   MG Biotherapeutics LLC
  </h1>
  <div style="display: none;">
   <table cellspacing="1" class="TableStyle-dnb_tablestyle_1" style="mc-table-style: url('../Resources/TableStyles/dnb_tablestyle_1.css');">
    <col class="TableStyle-dnb_tablestyle_1-Column-Column1">
    </col>
    <col class="TableStyle-dnb_tablestyle_1-Column-Column1">
    </col>
    <col class="TableStyle-dnb_tablestyle_1-Column-Column1">
    </col>
    <thead>
     <tr class="TableStyle-dnb_tablestyle_1-Head-Header1">
      <th class="TableStyle-dnb_tablestyle_1-HeadE-Column1-Header1">
       DUNS
      </th>
      <th class="TableStyle-dnb_tablestyle_1-HeadE-Column1-Header1">
       Hoovers ID
      </th>
      <th class="TableStyle-dnb_tablestyle_1-HeadD-Column1-Header1">
       Tier
      </th>
     </tr>
    </thead>
    <tbody>
     <tr class="TableStyle-dnb_tablestyle_1-Body-Body1">
      <td class="TableStyle-dnb_tablestyle_1-BodyB-Column1-Body1" style="text-align: center;">
        149390200
      </td>
      <td class="TableStyle-dnb_tablestyle_1-BodyB-Column1-Body1" style="text-align: center;">
       138672
      </td>
      <td class="TableStyle-dnb_tablestyle_1-BodyA-Column1-Body1" style="text-align: center;">
       3
      </td>
     </tr>
    </tbody>
   </table></div><MadCap:snippetBlock src="../Resources/Snippets/Master/Editorial/H2 Synopsis.flsnp" /><p>
   <company id="13560">
    Genzyme
   </company>
   and
   <company id="10981">
    Medtronic
   </company>
   are out to prove that it doesn't just take time to heal a broken heart. The two companies' joint venture, MG Biotherapeutics, was created in 2004 to develop new treatments for heart attacks and other cardiovascular conditions. The venture conducts biotechnology research and development programs, including programs seeking to use cellular grafting therapies to repair damaged heart tissue. MG Biotherapeutics is also engaged in the development of a less-invasive, catheter-based delivery system for cell-based therapies using Medtronic's technologies.
  </p><MadCap:snippetBlock src="../Resources/Snippets/Master/Editorial/XML text end.flsnp" /></body>
</html>
